The Company has entered into a Share Purchase Agreement with Inviga Healthcare Fund I in relation to the divestment by way of sale of the entire equity shares held by the Company in BACC ....
HCG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts less than Nifty Microcap 250 and 0.3 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
HCG has entered into a Share Purchase Agreement to sell its entire stake in BACC Health Care Private Limited to Inviga Healthcare Fund I for INR 37.64 crore (approx. INR 9.41 crore of which is deferred over 18 months). BACC operates in fertility and reproductive healthcare, which HCG explicitly states is not its core business. BACC contributed 4.45% of HCG's standalone revenue (INR 60.45 crore) and 1.09% of standalone net worth (INR 17.53 crore) in FY 2025-26. The transaction qualifies as a related party transaction as the buyer, Inviga Healthcare Fund I, is controlled by Dr. B.S. Ajaikumar, HCG's promoter and non-executive chairman. The deal was approved by the Board and Audit Committee and is expected to close within 4-5 weeks. The consideration was based on an independent third-party valuation.
This is a small, non-core asset sale that will have minimal financial impact on HCG given BACC's marginal contribution to revenue and net worth. The related party nature and deferred consideration may attract regulatory scrutiny, but the transaction is disclosed as arm's length with independent valuation.